Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of...

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile...

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024. This is the fourth year in a row that Viatris has...

Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah...

Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah...

Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A....

Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer")...

Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All...